IP Library › Granted Patent US 12,582,605
Granted Patent B2
US 12,582,605 · App. 16/512,967 · Granted Mar 24, 2026

Extended release formulations of cannabinoids

Inventors: Reinhard Nowak (Lörrach, DE); Zafar Iqbal (Sloatsburg, NY); Neha Chavan (Jamaica, NY)
Assignee: Glatt GmbH
A61K9/1652A61K9/0053A61K9/0056A61K9/1611A61K9/1617A61K9/1623A61K9/1635A61K9/1658A61K9/1664A61K9/1676A61K9/48A61K31/352A61K31/658A61K36/3482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,605
App. No.
16/512,967
Granted
Mar 24, 2026
Kind
B2
Abstract

Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, one or more surfactants, and a core. The core may comprise a porous bead. The one or more cannabinoids may comprise Δ9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

Claims (39)

1 . A composition for extended release of one or more cannabinoids, the composition comprising a population of particles, wherein each particle comprises:

the one or more cannabinoids;

one or more drug-releasing agents which comprise one or more gel-forming agents;

a core; and

one or more surfactants;

wherein the composition releases the one or more cannabinoids over a period of at least 6 hours;

wherein the core comprises a calcium carbonate bead or calcium phosphate bead;

wherein the cannabinoids, gel-forming agents, and surfactants form a substantially homogeneous mixture loaded onto the core; and

wherein the particles do not comprise a release-mediating layer external to the mixture.

2 . The composition of claim 1 , wherein the one or more cannabinoids comprises Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination thereof.

3 . The composition of claim 1 , wherein the one or more gel-forming agents is selected from glyceryl monooleate, glycerol monostearate, soybean oil, propylene glycol monopalmitostearate, carboxypolymethylene, hydroxypropyl cellulose, hydroxypropyl methycellulose, carboxymethyl cellulose, chitosan, acacia gum, alginate gums, carrageenan, and guar gum.

4 . The composition of claim 3 , wherein the one or more gel-forming agents comprises glycerol monooleate.

5 . The composition of claim 1 , wherein the core comprises one or more pores that extend from the surface of the core.

6 . The composition of claim 5 , wherein the one or more pores contain the one or more cannabinoids, the one or more drug-releasing agents, and the one or more surfactants.

7 . The composition of claim 6 , wherein the one or more pores are configured such that the one or more drug-releasing agents is located in the one or more pores closer to the surface of the core than the one or more cannabinoids and the one or more surfactants.

8 . The composition of claim 1 , wherein the surfactant is selected from the group consisting of sorbitan esters, ethoxylated sorbitan esters, fatty acid esters, polyalcohols, ethoxylated polyalcohols, ethoxylated linear alcohols, ethoxylated alkyl phenols, amine derivatives, amide derivatives, alkylpolyglucosides, ethyleneoxide-propyleneoxide copolymers, thiols, thiol derivatives, poloxamers, polyethylene glycol-fatty acid esters, lecithins, and mixtures thereof.

9 . The composition of claim 8 , wherein the one or more surfactants is selected from polysorbates and polyethylene glycol esters of ricinoleic acid.

10 . The composition of claim 1 , wherein the ratio of the one or more surfactants to the one or more drug-releasing agents is about 1:10 to about 10:1 by weight.

11 . The composition of claim 10 , wherein the ratio of the one or more surfactants to the one or more drug-release agents is about 1:1 by weight.

12 . The composition of claim 1 , wherein each particle further comprises one or more solubilizers.

13 . The composition of claim 12 , wherein the one or more solubilizers comprises an oil, glyceride, an alcohol, a hydroalcoholic mixture, or a combination thereof.

14 . The composition of claim 12 , wherein the ratio of the (one or more cannabinoids+the one or more drug-releasing agents+the one or more surfactants+the one or more solubilizers) to the core is about 2:1 to about 3:1 by weight.

15 . The composition of claim 1 wherein the core comprises a calcium carbonate bead.

16 . The composition of claim 1 wherein the core comprises a calcium phosphate bead.

17 . A composition for extended release of one or more cannabinoids, the composition comprising a population of particles, wherein each particle comprises:

about 1% to about 20% w/w of the one or more cannabinoids;

about 5% to about 15% w/w of one or more solubilizers;

about 15% to about 35% w/w of one or more drug-releasing agents;

about 20% to about 45% w/w of a core; and

about 15% to about 35% w/w of at least one surfactant,

wherein the composition releases the one or more cannabinoids over a period of at least 6 hours;

wherein the core comprises a calcium carbonate bead or calcium phosphate bead;

wherein the cannabinoids, gel-forming agents, and surfactants form a substantially homogeneous mixture loaded onto the core; and

wherein the particles do not comprise a release-mediating layer external to the mixture.

18 . The composition of claim 17 wherein the core comprises a calcium carbonate bead.

19 . The composition of claim 17 wherein the core comprises a calcium phosphate bead.

20 . A method of treating a health issue in a subject in need thereof, comprising administering the composition of claim 1 to the subject, wherein the health issue is selected from the group consisting of pain, nausea, sleep apnea, stress disorders, inflammation, depression, anxiety, epilepsy, schizophrenia, migraines, arthritis, weight loss, poor appetite, and combinations thereof.

21 . The method of claim 20 , wherein the composition is administered orally.

22 . The method of claim 21 , wherein prior to administration, the composition is sprinkled on food or nutrient that is solid, semi-solid, or liquid; into water; or into other types of liquid drink.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2020
From: NOWAK, REINHARD; IQBAL, ZAFAR; CHAVAN, NEHA
To: GLATT GMBH
Reel/Frame 052173/0751 →
Continuity (2)
Provisional Application 62700107 · Jul 18, 2018
Related Publication 20200046787A1 · Feb 13, 2020
References Cited (51)
US 5662932A · Amselem et al. · 1997 [cited by applicant]
US 5891496A · Hannah et al. · 1999 [cited by applicant]
US 6328992B1 · Brooke et al. · 2001 [cited by applicant]
US 6354728B1 · Bretschneider et al. · 2002 [cited by applicant]
US 6380175B1 · Hussain et al. · 2002 [cited by applicant]
US 6383513B1 · Watts et al. · 2002 [cited by applicant]
US 6509005B1 · Peart et al. · 2003 [cited by applicant]
US 6713048B2 · Peart et al. · 2004 [cited by applicant]
US 6946150B2 · Whittle · 2005 [cited by applicant]
US 7993595B2 · Jacob et al. · 2011 [cited by applicant]
US 8597685B2 · Jacob et al. · 2013 [cited by applicant]
US 10179109B2 · Bosse et al. · 2019 [cited by applicant]
US 20120231083A1 · Carley · 2012 [cited by examiner]
US 20160022627A2 · Smith · 2016 [cited by applicant]
US 20160051480A1 · Taha · 2016 [cited by applicant]
US 20160235673A1 · Preisig · 2016 [cited by examiner]
US 20180085308A1 · Renwick et al. · 2018 [cited by applicant]
US 20180214412A1 · Renwick et al. · 2018 [cited by applicant]
US 20180264013A1 · Dill · 2018 [cited by applicant]
US 20180325861A1 · Domb · 2018 [cited by examiner]
US 20190254302A1 · Abbaspourrad · 2019 [cited by examiner]
US 20200046643A1 · Nowak · 2020 [cited by examiner]
US 20200094955A1 · Selfridge · 2020 [cited by examiner]
CN 1886117 · 2006 [cited by applicant]
EP 1125629 · 2001 [cited by applicant]
EP 1325775 · 2003 [cited by applicant]
EP 1361864 · 2013 [cited by applicant]
WO WO2002064109 · 2002 [cited by applicant]
WO WO04052607 · 2004 [cited by applicant]
WO WO2008027442 · 2008 [cited by applicant]
WO WO2016144376 · 2016 [cited by applicant]
WO WO2016205923 · 2016 [cited by applicant]
WO WO2017072762 · 2017 [cited by applicant]
WO WO2018035030 · 2018 [cited by applicant]
WO WO2018071581 · 2018 [cited by applicant]
WO WO2019159174 · 2019 [cited by applicant]
The Specialty Excipient: Neusilin, Fuji Chemicals Industries, Sep. 2015. (Year: 2015). [cited by examiner]
International Search Report for Application No. PCT/IB2019/000840 dated Jan. 3, 2020. [cited by applicant]
Written Opinion of the International Search Authority for Application No. PCT/IB2019/000840 dated Jan. 3, 2020. [cited by applicant]
Written Opinion of the International Search Authority for Application No. PCT/IB2019/000847 dated Jan. 20, 2020. [cited by applicant]
International Search Report for Application No. PCT/IB2019/000847 dated Jan. 20, 2020. [cited by applicant]
Written Opinion of the International Search Authority for Application No. PCT/IB2019/0000857 dated Jan. 21, 2020. [cited by applicant]
International Search Report for Application No. PCT/IB2019/000857dated Jan. 21, 2020. [cited by applicant]
Written Opinion of the International Search Authority for Application No. PCT/IB2019/000860 dated Jan. 20, 2020. [cited by applicant]
International Search Report for Application No. PCT/IB2019/000860 dated Jan. 20, 2020. [cited by applicant]
U.S. Non-Final Office Action issued for corresponding U.S. Appl. No. 16/513,068 dated May 14, 2020. [cited by applicant]
Parker, W, 2009, Alcohol-containing pharmaceuticals, The American Journal of Drug and Alcohol Abuse, vol. 9, 195-209; screenshot from https ://pubmed.ncbi.nlm.nih.gov/7171081 / (Year: 2009). [cited by applicant]
U.S. Non-Final Office Action issued for corresponding U.S. Appl. No. 16/513,154 dated May 19, 2021. [cited by applicant]
Mydayis, “How Mydayis works”, 2020, screenshot of https://www.mydayis.com/adhd-treatment/how-it-works (Year: 2020). [cited by applicant]
Non-Final Office Action for corresponding U.S. Appl. No. 16/513,068 dated Nov. 9, 2021. [cited by applicant]
U.S. Non-Final Office Action issued for corresponding U.S. Appl. No. 16/513,068 dated Oct. 8, 2020. [cited by applicant]